Evidence for systems that carry regulated work.
Source-backed reporting and analysis connected to the companies, capabilities, authorities, and operating domains it affects.
Octave’s current life-sciences page identifies Reliance Life Sciences Compliance as formerly ETQ Reliance and says the rebrand keeps core functionality and performance consistent. That continuity statement is source evidence, but a regulated team still needs a controlled decision on whether legal, technical, documentation, support, or configuration changes affect the validated system.
SimplerQMS describes a life-sciences quality platform and states that its company holds ISO 13485 and ISO/IEC 27001 certifications. Those supplier-level statements are not evidence that a customer's exact release, configured workflow, integrations, intended use, or regulated records have been validated.
EXTEDO describes an end-to-end regulatory information management platform whose registration, document, quality, submission, and safety hubs can be used individually or together. That architecture still requires explicit contracts for the identity, version, status, authority, and receipt passed between each governed record and accountable team.
Scilife describes controlled printing and reconciliation alongside its document-management workflows. A printed copy still needs a durable identity, point-of-use owner, issuance history, reconciliation state, and retirement evidence before teams can know which instruction was available for regulated work.
EMA says the PLM web-based electronic Application Form becomes mandatory for human Centrally Authorised Product variation submissions on September 1, 2026, with justified technical exceptions for continued interactive-PDF use. Regulatory operations need to preserve the applicable form path, impediment, support evidence, submission package, and receipt outcome as separate controlled facts.
Ennov presents its Quality Suite as one application for managing and tracking quality documentation, processes, and data, with document management, quality management, and training in the suite. A unified record can make work visible and reviewable, but it does not by itself establish that a configured process was suitable, followed, or effective for its intended regulated use.
A shared compliance environment can connect quality and regulatory work without turning a quality disposition into a registration decision—or a regulatory status into quality approval.
MasterControl documents configurable quality-event forms, rules-based routing, connected quality records, and AI-supported summaries and trend identification. Those functions can organize investigation, but the event, related change or training record, root-cause conclusion, and accountable disposition should remain separately evidenced.
Veeva documents one shared platform and data model across four regulatory applications. That connection should preserve the different states of a registration, submission plan, published dossier, authority correspondence, and historical archive.
The drug CGMP definitions connect a lot number to a batch or lot's complete manufacturing and distribution history. That identifier supports traceability, but it does not by itself show that acceptance criteria were met or that quality authorized release.
The finished-pharmaceutical CGMP rule connects qualification and continuing training to assigned functions and the operations a person performs. A completed annual course, learning-system badge, or attendance total does not by itself establish that qualification.
The guideline assigns the pharmaceutical company responsibility for controlling outsourced activities and purchased materials through prior assessment, written responsibilities, monitoring, and review.
The production-record rule connects quality-unit review, batch release, investigation beyond the first affected batch, written conclusions, and follow-up instead of allowing a passing final result to erase an unexplained event.
The pharmaceutical quality-system model connects a proposed change to risk-based evaluation before implementation and a check afterward that objectives were achieved without harming product quality.
Annex 11 requires formal responsibility boundaries when third parties support GMP computerised systems. A vendor package cannot substitute for the regulated user's lifecycle evidence.
Part 11 applies to specified electronic records and signatures in an FDA-regulated context. A system label cannot replace the first question: which record requirement, use, and retention obligation is in scope?
ICH Q9(R1) treats risk as a lifecycle decision process, including computerized systems. Buyers should test evidence, review triggers, and human authority.
The February guidance focuses assurance effort on software risk and confidence rather than prescribing one validation-document package, giving buyers a sharper way to examine vendor evidence and intended use.
